Subject Index

A

acidosis
  in patients on RDT, 200
acute glomerulonephritis
  severe oliguric, 273
acute renal failure
  carbenicillin half-life in, 207
  in severe acute glomerulonephritis, 272
  shunts for, 393
adsorption
  of dialysate, 63
age
  effect on RDT and transplant results, 28, 254
alkalosis
  in patients on RDT, 200
aminoacid
  infusion, 175
aminoacids
  in plasma of chronic renal failure, 167
  in urine of chronic renal failure, 167
ammonia
  in blood during dialysate regeneration, 67
Amphotericin B
  389
anaemia
  in patients on RDT, 86, 94
angikeratoma (Fabry)
  12
antilymphocyte serum (ALS)
  336
arterial occlusion
  in transplant rejection, 17, 322, 352
arteriovenous fistulae
  aneurysms on, 417
  blood pressure in patients with, 48
  blood volume in patients with, 48
  cardiac output in patients with, 39, 49
  central venous pressure in, 48
  infections in, 37, 416
  multiple, 35
  proximal, 42
  saphenofemoral, 413
  using free saphenous graft, 403
  using sup. femoral artery, 408, 413
Australia antigen
  see hepatitis-associated antigen

B

bone biopsy
  in patients on RDT, 128, 133, 154
bone disease
  see osteodystrophy

calciun
  absorption in patients on RDT, 118
  carbonate therapy, 141
  infusion test, 133
  in skin of patients, 146
  whole body, 126
cannulae
  see shunts
carbenicillin
  half-life in renal failure, 207
cardiac failure
  with multiple access sites, 35
cardiac output
  during RDT, 492
  in patients with fistulae or shunts, 48, 492
cardiac tamponade
  during RDT, 495
carotenoids
  in chronic renal failure, 217
central venous pressure
  with arteriovenous fistulae, 48
cephalosporins
  379
charcoal
  activated, 467
  removal of pyrogens by, 467
children
  psychosocial adjustment of on RDT, 270, 366
  RDT in, 261, 366
  transplantation in, 366
chloramphenicol
  381
25-OH-cholecalciferol
  265
chronic renal failure
  see regular dialysis treatment
  from neurogenic bladder, 508
clearance
  see dialysance
colinisin
  377
complement
  in severe acute glomerulonephritis, 273
concentrate
  458
cortisol
  response to insulin during RDT, 225
cramps
  using glucose free, high Na+ dialysate, 55
cyproheptadine
  in transplant rejection, 322

518
Goodpasture's syndrome

Gouty nephropathy

Growth
- during RDT, 261
- growth hormone
  - response to hypoglycaemia on RDT, 225

Haemodialysers
- 6
  - AB Gambro, 7, 430
  - blood-circuit monitoring, 476
  - capillary film disposable, 422
  - disposable Kiil, 424
  - flatpack disposable, 437
  - Kiil
    - performance evaluation, 484
    - recirculating dialysate, 480
    - testing of batches, 484
  - membrane support, 440
  - new disposable, 419
  - performance comparison, 430
  - Rhone Poulenc, 7
  - small parallel flow, 442
  - sterilisation of, 464
  - Ultraflo 100, 69, 430

Haemodialysis
- 3
  - effect on parathormone, 151
  - membranes, 446
  - water for, 462
  - heparin
    - in treatment of severe glomerulonephritis, 273

Hepatitis
- associated (HA, SH, Au) antigen in, 5, 235, 442, 490
- in dialysis units, 5, 235, 242, 490

Home RDT
- mortality, 3, 26
- effect of housing on, 248

Housing
- effect of home RDT, 248

Hyperacute rejection
- 314

Hyperparathyroidism, 2°
- during RDT, 126, 133, 141, 146, 151, 265
- following transplantation, 151

Hyperpigmentation
- in chronic renal failure, 217

Hypothalamic-pituitary axis
- response to insulin on RDT, 225

Hypophosphataemia
- calcium carbonate therapy in, 143

Immunosuppression
- and erythropoietin, 259
- by antilymphocyte serum, 336

Infections
- in arteriovenous fistulae, 37, 416

Insulin
- disappearance in anephric man, 225
- growth hormone, cortisol response to, 225
iron  
absorption in chronic renal failure, 81  
in anaemia on RDT, 81, 87  
Fe$^{59}$ uptake following transplantation, 359  
ischaemic time  
309, 505

K

kanamycin  
375
kidney  
storage, 309
Kiil  
see haemodialyser

L

leucocytes  
in ‘hyperacute’ rejection, 314
lipochromes  
in chronic renal failure, 217
lupus nephritis  
10
lymphocytes  
in peripheral blood in rejection, 331

M

magnesium  
in skin in chronic renal failure, 147
melanin  
in chronic renal failure, 217
membrane  
evaluation, 446  
support for haemodialysers, 440
methylguanidine  
166
metastatic calcification  
144
mixed lymphocyte culture  
during ALS treatment, 336
mortality  
during RDT, 4, 20, 25, 254  
following transplantation, 27
muscle biopsy  
in chronic renal failure, 175

N

nalidixic acid  
382
nephrectomy  
effect on insulin disappearance, 225
neurogenic bladder  
causing chronic renal failure, 508
neuropathy  
during RDT, 9
nitrofurantoin  
383
nitrogen  
incorporation, 161
nitrogen balance  
in chronic renal failure, 161
norethandrolone  
in anaemia of RDT, 87

O

osteodystrophy  
during RDT, 9, 104, 126, 133, 141, 151, 265
oxygen  
consumption on RDT, 492  
tension in blood, 200, 492

P

parathormone  
in plasma following transplantation, 151  
in plasma on RDT, 151
parathyroidectomy  
during RDT, 134, 143, 146
penicillins  
372
platelets  
in rejection, 322
polycystic nodosa  
12
polymorphonuclear leucocytes  
in ‘hyperacute’ rejection, 314
potassium  
in skin in chronic renal failure, 147  
total body on RDT, 193
pregnancy  
following transplantation, 19  
on RDT, 9
proteins  
muscle, 175  
plasma  
during RDT, 175, 182  
in chronic renal failure, 175
psychosocial adjustment  
in children, 279, 366
pyrogens  
467

R

regular dialysis treatment  
acidosis during, 200, 492  
alkalosis during, 200, 492  
anæmia during, 86, 94  
anti-biotic treatment, 371  
blood loss with dialysis, 69  
cardiac output during, 48, 492  
cardiac tamponade during, 495  
cortisol response during, 225  
data chart for, 502  
diet in, 497  
effect on melanin and carotenoids, 217  
growth hormone response during, 225, 268  
hepatitis during, 5, 235, 242, 490  
hepatitis associated (HA, SH, Au) antigen  
in, 4, 235, 249, 490  
hypothalamic-pituitary-adrenal axis  
during, 225  
in children, 261, 366  
in home, 448  
insulin disappearance during, 225  
mathematical model for, 497  
mortality during, 4, 20, 25, 254  
oxygen consumption during, 492  
plasma bicarbonate during, 200, 492  
plasma parathormone during, 151  
rehabilitation during, 8, 30, 259
serum fluoride during, 110
serum proteins during, 175, 182
total body potassium during, 193
transfusion during, 235
unit for, 486
whole body Ca in, 126

rehabilitation
following transplantation, 30
on RDT, 8, 30, 259

renal transplantation
17
cadaver donors for, 17
diseases requiring, 16
erythropoietin level following, 359
hepatitis associated (HA, SH, Au) antigen following, 490
in children, 366
kidney storage for, 399
living donors for, 16
mortality following, 22, 27
plasma parathormone, following, 151
rehabilitation following, 30
rejection
arterial occlusion in, 17, 322, 352
cyproheptadine for, 322
effect on erythropoietin, 359
‘hyperacute’, 314
peripheral lymphocytes in, 336
platelets in, 322
polymorphs in, 314
surgical technique of, 505

reverse osmosis
462

RNA synthesis
in lymphocytes in rejection, 331

saphenofemoral vein graft
403, 415

SH antigen
see hepatitis-associated antigen

shunts
dacron band on, 395
drill for declotting, 397
for acute renal failure, 393
into superficial femoral artery, 408

shunts, silaric external
and fistulae in same patient, 35
blood pressure with, 48
blood volume with, 48
cardiac output with, 48
central venous pressure with, 48
pulse rate with, 48

skin biopsy
146

skin grafts
in ALS treatment, 337

sodium
in skin of uraemic patients, 148

streptomycin
374

sulphonamides
385

superficial femoral artery
for dialysis, 408, 413
surfactant
in ‘uraemic lung’, 286

tetracyclines
384
testosterone
in anaemia on RDT, 94
tissue typing
18

transplantation
306 renal transplantation
TTP (thrombotic thrombocytopenic purpura)

ultrafiltration
428, 435, 438, 474

uraemia
see chronic renal failure, and acute renal failure
‘uraemic lung’
286
urea
synthesis, 161
urysease
for dialysate regeneration, 419
urochromes
in chronic renal failure, 217

vitamin A
220

vitamin D
treatment, 118, 134, 265

water
for dialysis, 462

Wegener’s granulomatosis
12

xenografts
323

zirconium oxide
63

zirconium phosphate
63